Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese

Alex Sparreboom, Antonio C Wolff, Ron H J Mathijssen, Etienne Chatelut, Eric K. Rowinsky, Jaap Verweij, Sharyn D. Baker

Research output: Contribution to journalArticle

Abstract

Purpose: Despite the rising prevalence of obesity, there is paucity of information describing how doses of anticancer drugs should be adjusted in clinical practice. Here, we assessed the pharmacokinetics of eight anticancer drugs in adults and evaluated the potential utility of alternative weight descriptors in dose calculation for the obese. Patients and Methods: A total of 1,206 adult cancer patients were studied, of whom 162 (13.4%) were obese (body mass index ≥ 30). Pharmacokinetic parameters were calculated using noncompartmental analysis, and compared between lean (body mass index ≤ 25) and obese patients. Results: The absolute clearance of cisplatin, paclitaxel, and troxacitabine was significantly increased in the obese (P <.023), but this was not observed for carboplatin, docetaxel, irinotecan, or topotecan (P <.17). For doxorubicin, the systemic clearance was statistically significantly reduced in obese women (P = .013), but not in obese men (P = .52). Evaluation of alternate weight descriptors for dose calculation in the obese, including predicted normal weight, lean body mass, (adjusted) ideal body weight, and the mean of ideal and actual body weight, indicated that, for most of the evaluated drugs, weight scalars used to calculate body-surface area should consider actual body weight regardless of size. Conclusion: The results suggest that a number of widely used empiric strategies for dose adjustments in obese patients, including a priori dose reduction or dose capping, should be discouraged.

Original languageEnglish (US)
Pages (from-to)4707-4713
Number of pages7
JournalJournal of Clinical Oncology
Volume25
Issue number30
DOIs
StatePublished - Oct 20 2007

Fingerprint

Ideal Body Weight
irinotecan
docetaxel
Weights and Measures
Pharmaceutical Preparations
Body Mass Index
Pharmacokinetics
Topotecan
Body Surface Area
Carboplatin
Doxorubicin
Obesity
Body Weight
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Sparreboom, A., Wolff, A. C., Mathijssen, R. H. J., Chatelut, E., Rowinsky, E. K., Verweij, J., & Baker, S. D. (2007). Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. Journal of Clinical Oncology, 25(30), 4707-4713. https://doi.org/10.1200/JCO.2007.11.2938

Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. / Sparreboom, Alex; Wolff, Antonio C; Mathijssen, Ron H J; Chatelut, Etienne; Rowinsky, Eric K.; Verweij, Jaap; Baker, Sharyn D.

In: Journal of Clinical Oncology, Vol. 25, No. 30, 20.10.2007, p. 4707-4713.

Research output: Contribution to journalArticle

Sparreboom, A, Wolff, AC, Mathijssen, RHJ, Chatelut, E, Rowinsky, EK, Verweij, J & Baker, SD 2007, 'Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese', Journal of Clinical Oncology, vol. 25, no. 30, pp. 4707-4713. https://doi.org/10.1200/JCO.2007.11.2938
Sparreboom, Alex ; Wolff, Antonio C ; Mathijssen, Ron H J ; Chatelut, Etienne ; Rowinsky, Eric K. ; Verweij, Jaap ; Baker, Sharyn D. / Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. In: Journal of Clinical Oncology. 2007 ; Vol. 25, No. 30. pp. 4707-4713.
@article{359686092cc446188167df82911823d5,
title = "Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese",
abstract = "Purpose: Despite the rising prevalence of obesity, there is paucity of information describing how doses of anticancer drugs should be adjusted in clinical practice. Here, we assessed the pharmacokinetics of eight anticancer drugs in adults and evaluated the potential utility of alternative weight descriptors in dose calculation for the obese. Patients and Methods: A total of 1,206 adult cancer patients were studied, of whom 162 (13.4{\%}) were obese (body mass index ≥ 30). Pharmacokinetic parameters were calculated using noncompartmental analysis, and compared between lean (body mass index ≤ 25) and obese patients. Results: The absolute clearance of cisplatin, paclitaxel, and troxacitabine was significantly increased in the obese (P <.023), but this was not observed for carboplatin, docetaxel, irinotecan, or topotecan (P <.17). For doxorubicin, the systemic clearance was statistically significantly reduced in obese women (P = .013), but not in obese men (P = .52). Evaluation of alternate weight descriptors for dose calculation in the obese, including predicted normal weight, lean body mass, (adjusted) ideal body weight, and the mean of ideal and actual body weight, indicated that, for most of the evaluated drugs, weight scalars used to calculate body-surface area should consider actual body weight regardless of size. Conclusion: The results suggest that a number of widely used empiric strategies for dose adjustments in obese patients, including a priori dose reduction or dose capping, should be discouraged.",
author = "Alex Sparreboom and Wolff, {Antonio C} and Mathijssen, {Ron H J} and Etienne Chatelut and Rowinsky, {Eric K.} and Jaap Verweij and Baker, {Sharyn D.}",
year = "2007",
month = "10",
day = "20",
doi = "10.1200/JCO.2007.11.2938",
language = "English (US)",
volume = "25",
pages = "4707--4713",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "30",

}

TY - JOUR

T1 - Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese

AU - Sparreboom, Alex

AU - Wolff, Antonio C

AU - Mathijssen, Ron H J

AU - Chatelut, Etienne

AU - Rowinsky, Eric K.

AU - Verweij, Jaap

AU - Baker, Sharyn D.

PY - 2007/10/20

Y1 - 2007/10/20

N2 - Purpose: Despite the rising prevalence of obesity, there is paucity of information describing how doses of anticancer drugs should be adjusted in clinical practice. Here, we assessed the pharmacokinetics of eight anticancer drugs in adults and evaluated the potential utility of alternative weight descriptors in dose calculation for the obese. Patients and Methods: A total of 1,206 adult cancer patients were studied, of whom 162 (13.4%) were obese (body mass index ≥ 30). Pharmacokinetic parameters were calculated using noncompartmental analysis, and compared between lean (body mass index ≤ 25) and obese patients. Results: The absolute clearance of cisplatin, paclitaxel, and troxacitabine was significantly increased in the obese (P <.023), but this was not observed for carboplatin, docetaxel, irinotecan, or topotecan (P <.17). For doxorubicin, the systemic clearance was statistically significantly reduced in obese women (P = .013), but not in obese men (P = .52). Evaluation of alternate weight descriptors for dose calculation in the obese, including predicted normal weight, lean body mass, (adjusted) ideal body weight, and the mean of ideal and actual body weight, indicated that, for most of the evaluated drugs, weight scalars used to calculate body-surface area should consider actual body weight regardless of size. Conclusion: The results suggest that a number of widely used empiric strategies for dose adjustments in obese patients, including a priori dose reduction or dose capping, should be discouraged.

AB - Purpose: Despite the rising prevalence of obesity, there is paucity of information describing how doses of anticancer drugs should be adjusted in clinical practice. Here, we assessed the pharmacokinetics of eight anticancer drugs in adults and evaluated the potential utility of alternative weight descriptors in dose calculation for the obese. Patients and Methods: A total of 1,206 adult cancer patients were studied, of whom 162 (13.4%) were obese (body mass index ≥ 30). Pharmacokinetic parameters were calculated using noncompartmental analysis, and compared between lean (body mass index ≤ 25) and obese patients. Results: The absolute clearance of cisplatin, paclitaxel, and troxacitabine was significantly increased in the obese (P <.023), but this was not observed for carboplatin, docetaxel, irinotecan, or topotecan (P <.17). For doxorubicin, the systemic clearance was statistically significantly reduced in obese women (P = .013), but not in obese men (P = .52). Evaluation of alternate weight descriptors for dose calculation in the obese, including predicted normal weight, lean body mass, (adjusted) ideal body weight, and the mean of ideal and actual body weight, indicated that, for most of the evaluated drugs, weight scalars used to calculate body-surface area should consider actual body weight regardless of size. Conclusion: The results suggest that a number of widely used empiric strategies for dose adjustments in obese patients, including a priori dose reduction or dose capping, should be discouraged.

UR - http://www.scopus.com/inward/record.url?scp=36048936308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36048936308&partnerID=8YFLogxK

U2 - 10.1200/JCO.2007.11.2938

DO - 10.1200/JCO.2007.11.2938

M3 - Article

C2 - 17947717

AN - SCOPUS:36048936308

VL - 25

SP - 4707

EP - 4713

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 30

ER -